BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SH, Kim HY, Kim SY. Atypical hemolytic uremic syndrome and eculizumab therapy in children. Korean J Pediatr 2018;61:37-42. [PMID: 29563942 DOI: 10.3345/kjp.2018.61.2.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
2 Bello-Marquez DC, Nieto-Rios JF, Serna-Higuita LM, Gonzalez-Vergara AJ. Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome. J Bras Nefrol 2021;43:440-4. [PMID: 32779691 DOI: 10.1590/2175-8239-JBN-2020-0050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]